AzTrials
AzTrials

T-Cell Non-Hodgkin LymphomaPhase 1NCT05377827

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

A Phase 1 study testing WU-CART-007 in people with T-Cell Non-Hodgkin Lymphoma and Acute Myeloid Leukemia, run by Washington University School of Medicine at 1 site in United States.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL) represent a significant unmet medical need. CAR T therapy has offered durable remissions and potential cures in some forms of hematologic malignancy, including B-cell acute lymphoblastic leukemia. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
WU-CART-007
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
1 siteUnited States
Study dates
10 Oct 2023to 30 Jun 2027
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients will have T-cell non-Hodgkin lymphoma with relapsed or refractory disease defined as one of the following:
  • Relapsed or refractory after at least 2 or more prior lines of therapy (for patients with anaplastic large cell lymphoma, they must have prior therapy brentuximab vedotin). For patients with T-PLL, only 1 or more prior line of therapy is required. OR
  • Relapsed after autologous or allogeneic hematopoietic cell transplant.
  • Permissible T-cell NHL subtypes will include:
  • angioimmunoblastic T-cell lymphoma (AITL)
  • enteropathy-associated T-cell lymphoma (EATL)
Show all 47Show fewer
  • monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)
  • peripheral T-cell lymphoma (PTCL) NOS
  • anaplastic large cell lymphoma (ALCL)
  • adult T-cell leukemia/lymphoma
  • T-cell prolymphocytic leukemia (T-PLL)
  • extranodal NK/T cell lymphoma
  • transformed mycosis fungoides/Sezary Syndrome
  • primary cutaneous gamma/delta T-cell lymphoma
  • hepatosplenic T cell lymphoma
  • Patients will have Acute Myeloid Leukemia (AML) (acute leukemia of ambiguous lineage may be enrolled and treated per the AML cohort) with relapsed or refractory disease unlikely to benefit from standard therapy defined as one of the following:
  • Primary refractory AML defined as:
  • Minor or no response to intensive induction chemotherapy with more than 15% blasts and less than 50% proportional reduction in blast percentage after C1^30 OR
  • Absence of morphological CR/CRi following either:
  • ≥ 2 cycles of intensive induction chemotherapy
  • ≥ 2 cycles of HMA plus venetoclax, or
  • ≥ 4 total cycles of an HMA OR
  • Morphologic relapse (≥ 5% bone marrow blasts) with either:
  • Initial CR duration < 1 year
  • Prior unsuccessful salvage attempt or allogeneic HCT
  • 2nd relapse or higher OR
  • Disease progression while on treatment with HMA+/-venetoclax for MDS/AML
  • Patients with a susceptible FLT3, IDH1 or IDH2 mutation should be resistant or intolerant to an agent targeting the specific mutation or otherwise be determined to be ineligible to receive a targeted agent by their treating physician.
  • Circulating blast count must be <30,000/µL by morphology or flow cytometry
  • Additional inclusion criteria for Cohorts A and B are:
  • CD7 positive expression must be demonstrated in malignant cells in bone marrow, peripheral blood, or lymph node biopsies (fresh or archival). For both Dose Escalation and Dose Expansion, any qualitative expression of CD7 will be permitted.
  • Age ≥ 18 years of age
  • Eastern Cooperative Oncology Group Performance Status ≤ 2
  • Adequate organ function as defined below:
  • Total bilirubin ≤ 2x ULN (unless the patient has Grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin).
  • AST(SGOT) and ALT(SGPT) ≤ 5x ULN
  • Creatinine within normal institutional limits OR creatinine clearance ≥ 30 mL/min/1.73 m2 by Cockcroft-Gault Formula
  • Oxygen saturation ≥ 90% on room air
  • Ejection fraction ≥ 40% confirmed by echocardiogram or MUGA
  • For T-NHL with bone marrow involvement and AML, no hematologic parameters are required. For T-NHL without bone marrow involvement, adequate hematologic parameters are required, including:
  • Hemoglobin ≥ 8 g/dL without transfusion within 7 days
  • Platelets ≥ 20,000 / uL without transfusion within 7 days
  • Absolute neutrophil count ≥ 500 / uL
  • The effects of WU-CART-007 on the developing human fetus are unknown. For this reason, women of childbearing potential and male patients (along with their female partners) are required to use two forms of acceptable contraception, including one barrier method, during participation in the study and for 12 months following the last dose of WU-CART-007. Should a woman (or the female partner of a male patient) become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Patients must have no other effective standard of care therapy options, and patients must be unwilling or unable to travel to another site for treatment.
  • Dose Escalation ONLY: The patient must be considered a candidate for allogeneic hematopoietic stem cell transplantation in the opinion of the treating physician, and an acceptable allogeneic hematopoietic stem cell donor must be identified prior to study enrollment in case a patient experiences toxicity post-infusion that necessitates rescue HSCT. The identified donor may be related, unrelated, haplo-identical or umbilical cord blood, and does not need to be medically cleared prior to screening or dosing. If none of the patients at the RP2D experience severe recurrent infections due to prolonged lymphopenia or otherwise require rescue HSCT (excluding elective HSCT due to treating physician's choice for treatment of underlying disease), subsequent patients will not require identification of a donor prior to enrollment in Dose Expansion.
  • Able to understand and willing to sign an IRB approved written informed consent document.

Who cannot join

  • Patients will be excluded from study entry for any of the following:
  • Received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.
  • Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.
  • Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:
  • < 100 days post alloHCT
  • < 6 weeks from prior donor leukocyte infusion
Show all 16Show fewer
  • Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.
  • < 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.
  • Previous treatment with any anti-CD7 directed therapy.
  • Known hypersensitivity to one or more of the study agents.
  • Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.
  • Confirmed HIV infection.
  • History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.
  • Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.
  • Symptomatic, uncontrolled hypotension.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Washington University School of Medicine

    St Louis, Missouri, 63110

Other trials in United States

About this study

Official title: Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL) represent a significant unmet medical need. CAR T therapy has offered durable remissions and potential cures in some forms of hematologic malignancy, including B-cell acute lymphoblastic leukemia. In AML, however, CAR T approaches have been limited by the lack of suitable antigens, as most myeloid markers are shared with normal hematopoietic stem cells and targeting of these antigens by CAR T therapy leads to undesirable hematologic toxicity. Similarly, T-NHL has not yet benefited from CAR T therapy due to a lack of suitable markers. One potential therapeutic target is CD7, which is expressed normally on mature T-cells and NK-cells but is also aberrantly expressed on ~30% of acute myeloid leukemias. CAR T therapy for patients with CD7+ AML and T-NHL will potentially offer a new therapeutic option which has a chance of offering durable benefit.

WU-CART-007 is a CD7-directed, genetically modified, allogeneic, fratricide-resistant chimeric antigen receptor (CAR) T-cell product for the treatment of CD7+ hematologic malignancies. These cells have two key changes from conventional, autologous CAR T-cells. First, because CD7 is present on normal T-cells including conventional CAR T products, CD7 is deleted from WU CART-007. This allows for targeting of CD7 without the risk of fratricide (killing of WU-CART-007 cells by other WU-CART-007 cells). Second, the T cell receptor alpha constant (TRAC) is also deleted. This makes WU CART 007 cells incapable of recognizing antigens other than CD7 and allows for the use of an allogeneic product without causing Graft-versus-Host-Disease (GvHD).

Being tested
WU-CART-007
Medical subject headings
Lymphoma, T-Cell, Leukemia, Myeloid, Acute, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, T-Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • WU-CART-007Biological

    Provided by Miltenyi Biotec

Study groups in NCT05377827
Study groupRoleWhat they receive
Dose Escalation Cohort A: WU-CART-007 T-NHLExperimentalPatients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
Dose Escalation Cohort B: WU-CART-007 leukemiaExperimentalPatients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
Dose Expansion Cohort A: WU-CART-007 T-NHLExperimentalPatients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
Dose Expansion Cohort B: WU-CART-007 leukemiaExperimentalPatients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recommended phase II dose (Dose Escalation only)

    -The recommended phase II dose (RP2D) will be determined independently for each disease cohort (CD7+ AML and T-NHL). The RP2D will not be greater than the maximum tolerated dose (MTD). However, the RP2D may be a lower dose level in certain circumstances:

    • If emerging toxicity at the MTD is unpredictable or undesirable for other reasons.
    • If clear evidence of efficacy is noted at lower doses with a cleaner safety profile.
    • If the cellular pharmacokinectic (cPK) profile that emerges results in similar numbers of clonal cells over time that is independent of administered dose level.
    • If longer follow-up on earlier patient cohorts suggests the emergence of delayed toxicity.

    Measured: Through completion of day 42 for all Part A participants (estimated to be 18 months and 42 days)

  2. Number of participants with complete metabolic response or partial metabolic response (Dose expansion only - Cohort A)

    -Per Lugano criteria for patients with T-cell lymphoma (T-NHL). Per Global Response Criteria for cutaneous T-cell lymphoma (CTCL). Per the T-PLL International Study Group criteria for T-cell prolymphocytic leukemia (T-PLL)

    Measured: Through completion of response assessments (estimated to be 24 months)

  3. Number of participants with complete remission, complete remission with incomplete blood count recovery, complete remission with partial hematologic recovery, or morphologic leukemia free state (Dose expansion only - Cohort B)

    -Per modified 2017 ELN criteria for patients with AML

    Measured: Through completion of response assessments (estimated to be 24 months)

Secondary outcomes (7)

  1. Number of participants with treatment-emergent adverse events as measured by CTCAE v 5.0

    -Treatment-emergent adverse events are those with an onset on or after the initiation of therapy, and, with the exception of cytokine release syndrome and neurotoxicity

    Measured: From start of treatment through completion of follow-up (estimated to be 24 months)

  2. Number of participants with cytokine release syndrome

    -Cytokine release syndrome will be graded accorded to the ASTCT Consensus Guidelines

    Measured: From start of treatment through Day 7 (estimated to be 8 days)

  3. Number of participants with immune effector cell-associated neurotoxicity syndrome (ICANS) as measured by ASTCT Consensus Grading

    Measured: From start of treatment through Day 7 (estimated to be 8 days)

  4. Duration of remission (DoR) (Dose Expansion only)

    • DoR for patients who achieve CR/CRi/CRMLFS/PR is measured from the time measurement criteria are met for CR/CRi/CRh/MLFS/PR (whichever is first recorded) until the first date that relapse is objectively documented.
    • Also includes patients who were treated at the recommended phase II dose in Dose Escalation.

    Measured: Through completion of response assessments (estimated to be 24 months)

  5. Relapse-free survival (RFS) (Dose Expansion only)

    • RFS is defined for patients who achieve CR/CRi/CRh/MLFS/PR as the duration of time measurement criteria are met for CR/CRi/CRh/MLFS/PR (whichever is first recorded) to time of relapse or death, whichever occurs first.
    • Also includes patients who were treated at the recommended phase II dose in Dose Escalation.

    Measured: Through completion of follow-up (estimated to be 24 months)

  6. Event-free survival (EFS) (Dose Expansion only)

    • EFS is defined for all patients and measured from the date of entry on study until treatment failure, relapse from CR, or death from any cause.
    • Also includes patients who were treated at the recommended phase II dose in Dose Escalation.

    Measured: Through completion of follow-up (estimated to be 24 months)

  7. Overall survival (OS) (Dose Expansion only)

    • OS is defined as the time from date of entry on study to time of death.
    • Also includes patients who were treated at the recommended phase II dose in Dose Escalation.

    Measured: Through completion of follow-up (estimated to be 24 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2022
  2. Study start10 Oct 2023
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Why it stopped: Drugs/Equipment Unavailable

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Model description
Two cohorts (AML and T-NHL) will enroll and be treated independently in the Dose Escalation portion of the study. Patients in each cohort will be treated following an accelerated titration 3+3 design, meaning that one patient will be treated at a dose level with continued escalation until a DLT is observed, at which point a traditional 3+3 design will be triggered in that cohort moving forward. Upon confirmation of the recommended phase 2 dose (RP2D) for either cohort, enrollment to the Dose Expansion portion of the study for that cohort will commence.
Masking
None (open label)
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05377827
Sponsor's protocol ID
202306200
Status last verified
Jul 2026
First submitted
11 May 2022
Last updated
21 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing WU-CART-007 in people with T-Cell Non-Hodgkin Lymphoma and Acute Myeloid Leukemia, run by Washington University School of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 47 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recommended phase II dose (Dose Escalation only) (time frame: Through completion of day 42 for all Part A participants (estimated to be 18 months and 42 days)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05377827.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in